rani therapeutics holdings inc - RANI

RANI

Close Chg Chg %
1.47 0.01 0.68%

Closed Market

1.48

+0.01 (0.68%)

Volume: 801.07K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Company Overview: rani therapeutics holdings inc - RANI

RANI Key Data

Open

$1.48

Day Range

1.44 - 1.49

52 Week Range

0.39 - 3.87

Market Cap

$143.40M

Shares Outstanding

97.55M

Public Float

79.32M

Beta

0.42

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.79

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

2.58M

 

RANI Performance

1 Week
 
-1.99%
 
1 Month
 
-7.50%
 
3 Months
 
208.33%
 
1 Year
 
4.23%
 
5 Years
 
N/A
 

RANI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About rani therapeutics holdings inc - RANI

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

RANI At a Glance

Rani Therapeutics Holdings, Inc.
2051 Ringwood Avenue
San Jose, California 95131
Phone 1-408-457-3700 Revenue 1.03M
Industry Biotechnology Net Income -30,018,000.00
Sector Health Technology Employees 105
Fiscal Year-end 12 / 2025
View SEC Filings

RANI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 37.95
Price to Book Ratio 22.99
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.866
Enterprise Value to Sales 40.937
Total Debt to Enterprise Value 0.706

RANI Efficiency

Revenue/Employee 9,790.476
Income Per Employee -285,885.714
Receivables Turnover 1.637
Total Asset Turnover 0.022

RANI Liquidity

Current Ratio 1.495
Quick Ratio 1.495
Cash Ratio 1.415

RANI Profitability

Gross Margin N/A
Operating Margin -4,824.903
Pretax Margin -5,504.28
Net Margin -2,920.039
Return on Assets -63.497
Return on Equity -404.065
Return on Total Capital -94.691
Return on Invested Capital -114.154

RANI Capital Structure

Total Debt to Total Equity 1,491.416
Total Debt to Total Capital 93.716
Total Debt to Total Assets 81.097
Long-Term Debt to Equity 665.161
Long-Term Debt to Total Capital 41.797
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rani Therapeutics Holdings Inc - RANI

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- - 2.72M 1.03M
-
Sales Growth
- - +488.10% -100.00%
-
Cost of Goods Sold (COGS) incl D&A
- 1.31M 822.00K 1.03M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
497.00K 1.31M 822.00K 1.03M
Depreciation
497.00K 1.31M 822.00K 1.03M
Amortization of Intangibles
- - - -
-
COGS Growth
- - -37.35% +25.06%
-
Gross Income
- - (1.31M) (822.00K)
-
Gross Income Growth
- - +37.35% +100.00%
-
Gross Profit Margin
- - - -
-
2021 2022 2023 2024 5-year trend
SG&A Expense
53.82M 62.14M 65.28M 49.60M
Research & Development
26.48M 36.61M 39.62M 26.68M
Other SG&A
27.34M 25.53M 25.65M 22.92M
SGA Growth
+227.82% +15.46% +5.05% -24.02%
Other Operating Expense
- - - -
-
Unusual Expense
- - 1.07M 3.71M
-
EBIT after Unusual Expense
(52.67M) (63.45M) (66.10M) (53.31M)
Non Operating Income/Expense
89.00K 1.25M 3.30M 1.76M
Non-Operating Interest Income
89.00K 1.25M 3.30M 1.76M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
466.00K 1.07M 5.08M 5.03M
Interest Expense Growth
+275.81% +129.83% +374.79% -1.02%
Gross Interest Expense
466.00K 1.07M 5.08M 5.03M
Interest Capitalized
- - - -
-
Pretax Income
(53.05M) (63.27M) (67.88M) (56.58M)
Pretax Income Growth
-218.26% -19.28% -7.28% +16.64%
Pretax Margin
- - -1,952.41% -5,504.28%
-
Income Tax
- - 41.00K 70.00K
-
Income Tax - Current - Domestic
- - 41.00K 70.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(53.09M) (63.34M) (67.88M) (56.58M)
Minority Interest Expense
(44.76M) (32.76M) (33.91M) (26.57M)
Net Income
(8.33M) (30.59M) (33.97M) (30.02M)
Net Income Growth
+50.12% -267.16% -11.06% +11.63%
Net Margin Growth
- - -306.62% -2,920.04%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(8.33M) (30.59M) (33.97M) (30.02M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(8.33M) (30.59M) (33.97M) (30.02M)
EPS (Basic)
-0.4226 -1.2843 -1.3319 -1.0542
EPS (Basic) Growth
+50.06% -203.90% -3.71% +20.85%
Basic Shares Outstanding
19.71M 23.82M 25.50M 28.48M
EPS (Diluted)
-0.4226 -1.2843 -1.3319 -1.0542
EPS (Diluted) Growth
+50.06% -203.90% -3.71% +20.85%
Diluted Shares Outstanding
19.71M 23.82M 25.50M 28.48M
EBITDA
(51.10M) (62.14M) (65.28M) (48.57M)
EBITDA Growth
-220.29% -21.60% -5.05% +25.59%
EBITDA Margin
- - -1,880.82% -4,724.90%
-

Snapshot

Average Recommendation BUY Average Target Price 9.25
Number of Ratings 3 Current Quarters Estimate -0.048
FY Report Date 12 / 2025 Current Year's Estimate -0.425
Last Quarter’s Earnings -0.12 Median PE on CY Estimate N/A
Year Ago Earnings -1.05 Next Fiscal Year Estimate -0.27
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 2 4 4
Mean Estimate -0.05 -0.09 -0.43 -0.27
High Estimates 0.01 -0.03 -0.35 -0.13
Low Estimate -0.14 -0.14 -0.58 -0.59
Coefficient of Variance -140.04 -91.51 -24.64 -79.49

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Rani Therapeutics Holdings Inc in the News